Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis

Masatoshi Hotta; Andrei Gafita; Johannes Czernin; Jeremie Calais

doi:10.2967/jnumed.121.263441

Research ArticleBRIEF COMMUNICATION

Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with ¹⁷⁷Lu-PSMA Therapy: A Multicenter Retrospective Analysis

Masatoshi Hotta, Andrei Gafita, Johannes Czernin and Jeremie Calais

Journal of Nuclear Medicine October 2022, 63 (10) 1484-1488; DOI: https://doi.org/10.2967/jnumed.121.263441

Masatoshi Hotta

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Andrei Gafita

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Johannes Czernin

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jeremie Calais

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Article Information

vol. 63 no. 10 1484-1488

DOI

https://doi.org/10.2967/jnumed.121.263441

PubMed

35273096

Published By

Society of Nuclear Medicine

Print ISSN

0161-5505

Online ISSN

2159-662X

History

Received for publication October 28, 2021
Accepted for publication February 22, 2022
Published online October 3, 2022.

Article Versions

previous version (March 10, 2022 - 13:10).
previous version (April 14, 2022 - 12:36).
You are viewing the most recent version of this article.

Author Information

Masatoshi Hotta,
Andrei Gafita,
Johannes Czernin and
Jeremie Calais

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California

For correspondence or reprints, contact Jeremie Calais (jcalais{at}mednet.ucla.edu).

View Full Text

Statistics from Altmetric.com

Cited By...

36 Citations
39 Citations
Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0

Wolfgang P. Fendler, Matthias Eiber, Mohsen Beheshti, Jamshed Bomanji, Jeremie Calais, Francesco Ceci, Steve Y. Cho, Stefano Fanti, Frederik L. Giesel, Karolien Goffin, Uwe Haberkorn, Heather Jacene, Phillip J. Koo, Klaus Kopka, Bernd J. Krause, Liza Lindenberg, Charles Marcus, Felix M. Mottaghy, Daniela E. Oprea-Lager, Joseph R. Osborne, Morand Piert, Steven P. Rowe, Heiko Schöder, Simon Wan, Hans-Jürgen Wester, Thomas A. Hope, Ken Herrmann

European Journal of Nuclear Medicine and Molecular Imaging 2023 50 5
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

Robert Seifert, Louise Emmett, Steven P. Rowe, Ken Herrmann, Boris Hadaschik, Jeremie Calais, Frederik L. Giesel, Robert Reiter, Tobias Maurer, Matthias Heck, Andrei Gafita, Michael J. Morris, Stefano Fanti, Wolfgang A. Weber, Thomas A. Hope, Michael S. Hofman, Wolfgang Peter Fendler, Matthias Eiber

European Urology 2023 83 5
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Clemens Kratochwil, Wolfgang P. Fendler, Matthias Eiber, Michael S. Hofman, Louise Emmett, Jeremie Calais, Joseph R. Osborne, Amir Iravani, Phillip Koo, Liza Lindenberg, Richard P. Baum, Murat Fani Bozkurt, Roberto C. Delgado Bolton, Samer Ezziddin, Flavio Forrer, Rodney J. Hicks, Thomas A. Hope, Levent Kabasakal, Mark Konijnenberg, Klaus Kopka, Michael Lassmann, Felix M. Mottaghy, Wim J. G. Oyen, Kambiz Rahbar, Heiko Schoder, Irene Virgolini, Lisa Bodei, Stefano Fanti, Uwe Haberkorn, Ken Hermann

European Journal of Nuclear Medicine and Molecular Imaging 2023 50 9
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer

Erolcan Sayar, Radhika A. Patel, Ilsa M. Coleman, Martine P. Roudier, Ailin Zhang, Pallabi Mustafi, Jin-Yih Low, Brian Hanratty, Lisa S. Ang, Vipul Bhatia, Mohamed Adil, Hasim Bakbak, David A. Quigley, Michael T. Schweizer, Jessica E. Hawley, Lori Kollath, Lawrence D. True, Felix Y. Feng, Neil H. Bander, Eva Corey, John K. Lee, Colm Morrissey, Roman Gulati, Peter S. Nelson, Michael C. Haffner

JCI Insight 2023 8 7
Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy

Ian Alberts, Robin Schepers, Konstantinos Zeimpekis, Hasan Sari, Axel Rominger, Ali Afshar-Oromieh

European Journal of Nuclear Medicine and Molecular Imaging 2023 50 3
177Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers

Amir Karimzadeh, Matthias Heck, Robert Tauber, Karina Knorr, Bernhard Haller, Calogero D’Alessandria, Wolfgang A. Weber, Matthias Eiber, Isabel Rauscher

Journal of Nuclear Medicine 2023 64 3
PSMA PET Tumor–to–Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study

Masatoshi Hotta, Andrei Gafita, Vishnu Murthy, Matthias R. Benz, Ida Sonni, Irene A. Burger, Matthias Eiber, Louise Emmett, Andrea Farolfi, Wolfgang P. Fendler, Manuel M. Weber, Michael S. Hofman, Thomas A. Hope, Clemens Kratochwil, Johannes Czernin, Jeremie Calais

Journal of Nuclear Medicine 2023 64 7
Is18F-FDG PET Needed to Assess177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis

Robert Seifert, Tugce Telli, Boris Hadaschik, Wolfgang P. Fendler, Phillip H. Kuo, Ken Herrmann

Journal of Nuclear Medicine 2023 64 5
How Many Theranostics Centers Will We Need in the United States?

Johannes Czernin, Jeremie Calais

Journal of Nuclear Medicine 2022 63 6
Prostate-Specific Membrane Antigen–Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes

Matteo Corpetti, Cristina Müller, Himisha Beltran, Johann de Bono, Jean-Philippe Theurillat

European Urology 2024 85 3

Article usage

Article usage: March 2022 to November 2024

	Abstract	Full	Pdf
Mar 2022	2948	0	118
Apr 2022	1247	0	65
May 2022	542	0	34
Jun 2022	468	0	28
Jul 2022	309	0	21
Aug 2022	222	0	4
Sep 2022	272	0	10
Oct 2022	1421	76	81
Nov 2022	440	33	47
Dec 2022	594	22	23
Jan 2023	598	10	34
Feb 2023	512	7	12
Mar 2023	567	20	30
Apr 2023	85	288	54
May 2023	71	232	68
Jun 2023	39	244	34
Jul 2023	51	292	37
Aug 2023	44	393	93
Sep 2023	60	355	84
Oct 2023	49	233	51
Nov 2023	91	217	47
Dec 2023	49	115	35
Jan 2024	31	233	136
Feb 2024	32	244	28
Mar 2024	45	178	51
Apr 2024	119	101	48
May 2024	59	149	42
Jun 2024	96	124	32
Jul 2024	213	201	48
Aug 2024	185	180	36
Sep 2024	66	128	172
Oct 2024	25	70	32
Nov 2024	34	93	42

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 63, Issue 10

October 1, 2022

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with ¹⁷⁷Lu-PSMA Therapy: A Multicenter Retrospective Analysis

Masatoshi Hotta, Andrei Gafita, Johannes Czernin, Jeremie Calais

Journal of Nuclear Medicine Oct 2022, 63 (10) 1484-1488; DOI: 10.2967/jnumed.121.263441

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with ¹⁷⁷Lu-PSMA Therapy: A Multicenter Retrospective Analysis

Masatoshi Hotta, Andrei Gafita, Johannes Czernin, Jeremie Calais

Journal of Nuclear Medicine Oct 2022, 63 (10) 1484-1488; DOI: 10.2967/jnumed.121.263441

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

Challenges with 177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice
Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
Is 18F-FDG PET Needed to Assess 177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis
177Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers
Clinical Trials of Prostate-Specific Membrane Antigen Radiopharmaceutical Therapy
Reply: What Does an Imaging "Selection" Claim Actually Mean?

Google Scholar

Keywords

metastatic castration-resistant prostate cancer
radionuclide therapy
PSMA PET
177Lu
VISION trial

Main menu

User menu

Search

Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with ¹⁷⁷Lu-PSMA Therapy: A Multicenter Retrospective Analysis

Article Information

Article Versions

Author Information

Statistics from Altmetric.com

Cited By...

Article usage

Article usage: March 2022 to November 2024

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords